Pyrido[2,3-d]pyrimidin-2(1H)-one,6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-,(1R)-

Independent reference data for Pyrido[2,3-d]pyrimidin-2(1H)-one,6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-,(1R)- (CAS 2252403-56-6), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy. It is additionally approved in combination with [panitumumab] for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior [fluorouracil]-, [oxaliplatin]- and [irinotecan]-based chemotherapy.Sotorasib is a small molecule inhibitor of the KRAS G12C mutant protein which is found in up to 13% of refractory cases of non-small cell lung cancer. Serum aminotransferase elevations are common during therapy with sotorasib, and a proportion of patients develop clinically apparent liver injury that can be severe.

Synonyms and trade names

Sotorasib; AMG-510; 2296729-00-3; AMG510; Lumakras; AMG 510; Kras G12C inhibitor 9; Kras mutant-targeting AMG 510; 2B2VM6UC8G; CHEBI:178199; RefChem:56869; 2252403-56-6; AMG-510 racemate; SOTORASIB RACEMATE; Lumykras; Sotorasib [INN]

What the public record says

Pyrido[2,3-d]pyrimidin-2(1H)-one,6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-,(1R)- · CAS 2252403-56-6 · C30H30F2N6O3. UNII 2B2VM6UC8G. Solubility: 1.3; Dissociation Constants: 8.06, 4.56.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.